Seminars in Oncology
Volume 33, Issue 5 , Pages 607-613 , October 2006

Mammalian Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Current Status and Future Applications

  • Allan J. Pantuck

      Affiliations

    • Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
    • Corresponding Author InformationAddress correspondence to Allan J. Pantuck, MD, Department of Urology, David Geffen School of Medicine at UCLA, 66-118 Center for Health Sciences, Box 951738, Los Angeles, CA 90095-1738.
    • ,
  • George Thomas

      Affiliations

    • Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Beckman Research Institute, and Comprehensive Cancer Center, Duarte, CA.
    • ,
  • Arie S. Belldegrun

      Affiliations

    • Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
    • ,
  • Robert A. Figlin

      Affiliations

    • Department of Urology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
    • Department of Medical Oncology and Experimental Therapeutics, City of Hope National Medical Center, Beckman Research Institute, and Comprehensive Cancer Center, Duarte, CA.

References 

  1. Jemal A, Spiegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev. 2003;17:2998–3010
  3. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909–918
  4. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2:489–501
  5. Abraham RT. Mammalian target of rapamycin: Immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol. 1998;10:330–336
  6. Hosoi H, Dilling MB, Liu LN, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol. 1998;54:815–824
  7. Hosoi H, Dilling MB, Shikata T, et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res. 1999;59:886–894
  8. Zhang Y, Gao X, Saucedo LJ, et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol. 2003;5:578–581
  9. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol. 2002;4:648–657
  10. Thomas GV. mTOR and cancer: Reason for dancing at the crossroads?. Curr Opin Genet Dev. 2006;16:78–84
  11. Bjornsti MA, Houghton PJ. The TOR pathway: A target for cancer therapy. Nat Rev Cancer. 2004;4:335–348
  12. Sawyers CL. Will mTOR inhibitors make it as cancer drugs?. Cancer Cell. 2003;4:343–348
  13. Wendel HG, De Stanchina E, Fridman JS, et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 2004;428:332–337
  14. Thomlinson R. Tumour anoxia and the response to radiation. Sci Basis Med Annu Rev. 1965;74–90
  15. Gray L, Conger A, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol. 1953;26:638–648
  16. Vaupel P, Hockel M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: Characterization and therapeutic relevance. Int J Oncol. 2000;17:869–879
  17. Harris AL. Hypoxia—A key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2:38–47
  18. Lorentz A, Jendrissek A, Eckardt KU, et al. Serial immunoreactive erythropoietin levels in autologous blood donors. Transfusion. 1991;31:650–654
  19. Semenza GL. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med. 2002;8:S62–S67
  20. Laughner E, Taghavi P, Chiles K, et al. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21:3995–4004
  21. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001;61:7992–7998
  22. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res. 2000;60:1541–1545
  23. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59:5830–5835
  24. Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: Implications for tumor angiogenesis and therapeutics. Cancer Res. 2000;60:1541–1545
  25. Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000;14:391–396
  26. Jiang BH, Jiang G, Zheng JZ, et al. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ. 2001;12:363–369
  27. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3:721–732
  28. Brugarolas JB, Vazquez F, Reddy A, et al. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell. 2003;4:147–158
  29. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer. 2002;2:673–682
  30. Gnarra JR, Glenn GM, Latif F, et al. Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin North Am. 1993;20:207–216
  31. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85–90
  32. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994;91:9700–9704
  33. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–275
  34. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000;2:423–427
  35. Maranchie JK, Vasselli JR, Riss J, et al. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell. 2002;1:247–255
  36. Kondo K, Klco J, Nakamura E, et al. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell. 2002;1:237–246
  37. Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15:807–826
  38. Gingras AC, Raught B, Sonenberg N. Control of translation by the target of rapamycin proteins. Prog Mol Subcell Biol. 2001;27:143–174
  39. Hidalgo M, Rowinsky E, Erlichman C, et al. CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study. Proc Am Soc Clin Oncol. 2000;19:726A;(abstr)
  40. Huang S, Bjornsti MA, Houghton PJ. Mechanisms of resistance to rapamycins. Drug Resist Updat. 2001;4:378–391
  41. Bouley A, Zumstein S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 2004;64:252–261
  42. Giles FJ, Albitar M. Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med. 2005;5:653–661
  43. Jonas A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: Its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett. 2005;10:479–498
  44. Boni JP, Leister C, Bender G, et al. Population pharmacokinetics of CCI-779: Correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther. 2005;77:76–89
  45. Raymond E, Alexandre J, Depenbrock H, et al. CCI-779, a rapamycin analogue with antitumor activity: A phase I study utilizing a weekly schedule. Proc Am Soc Clin Oncol. 2000;19:187a;(abstr)
  46. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol. 2004;16:564–575
  47. Cho D, Signoretti S, Regan M, et al. Low expression of surrogates for mTOR pathway activation predict for resistance to CCI-779 in patients with advanced renal cell carcinoma (RCC). Philadelphia, PA: ASCO/AACR/EORTC International Conference on Medical Therapeutics; 2005;
  48. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A. 2001;98:10314–10319
  49. Choe G, Horvath S, Cloughesy TF, et al. Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003;63:2742–2746
  50. Thomas GV, Horvath S, Smith BL, et al. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin Cancer Res. 2004;10:8351–8356
  51. Pantuck AJ, Seligson D, Wu H, et al. Characterization of the mTOR pathway in renal cell carcinoma and its use in predicting patient selection for agents targeting this pathway. J Urol. 2005;173:96a;(abstr)
  52. Thomas GV, Tran C, Mellinghof I, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006;12:122

PII: S0093-7754(06)00268-5

doi: 10.1053/j.seminoncol.2006.06.002

Seminars in Oncology
Volume 33, Issue 5 , Pages 607-613 , October 2006

Article Tools

* Image Usage & Resolution